Celltrion USA announces submission of the Biologics License Application (BLA) of novel subcutaneous formulation of CT-P13 to U.S. Food and Drug Administration
CHICAGO--(BUSINESS WIRE)--Dec 22, 2022--
New Jersey United States Iris Shaffer Infliximab Biosimilar Public Health Service Act Subcutaneous Administration
Source: wsiltv.com